Skip to main content

Table 1 Characterization of PRO-169

From: Safety and tolerability evaluation after repeated intravitreal injections of a humanized anti-VEGF-A monoclonal antibody (PRO-169) versus ranibizumab in New Zealand white rabbits

Test Method PRO-169
Quality Appearance Slightly yellow, opalescent liquid
pH 6.2
Charge of heterogeneity CEX-HPLC 55.1% main peak, 34.3% acidic variants, and 10.7 basic variants
Structure Intact mass LC/MS, G0F/G0F 149201 Da
Deglycosylated partially reduced LC/MS Light chain mass = 23450.8 Da, deglycosylated heavy chain mass = 49717.5 Da
Oligosaccharide profile N-Glycan profiling 79.2% G0, 16.1% G1, and 0.9% G2
Other SPR KD = 6.54 × 10−6
Vitreous Pharmacokinetics SPR CMax ± SD = 593.7 ± 42.6 µg/ml
TMax ± SD = 0.53 ± 0.8 days
T1/2 ± SD = 4.99 ± 0.9 days
  1. CEX-HPLC: cation exchange chromatography-high performance liquid chromatography; CMax: peak maximum concentration; KD: binding constant; LC/MS: liquid chromatography/mass spectrometry; SD: standard deviation; SPR: surface plasmon resonance; T1/2: half-life time; TMax: time to maximal concentration